JP2020509022A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020509022A5 JP2020509022A5 JP2019547113A JP2019547113A JP2020509022A5 JP 2020509022 A5 JP2020509022 A5 JP 2020509022A5 JP 2019547113 A JP2019547113 A JP 2019547113A JP 2019547113 A JP2019547113 A JP 2019547113A JP 2020509022 A5 JP2020509022 A5 JP 2020509022A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- hydrogen
- protecting group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 68
- 229910052739 hydrogen Inorganic materials 0.000 claims 67
- 239000001257 hydrogen Substances 0.000 claims 67
- 125000000623 heterocyclic group Chemical group 0.000 claims 55
- 125000001072 heteroaryl group Chemical group 0.000 claims 50
- 150000002431 hydrogen Chemical class 0.000 claims 49
- 125000003118 aryl group Chemical group 0.000 claims 37
- 125000004452 carbocyclyl group Chemical group 0.000 claims 36
- 125000000304 alkynyl group Chemical group 0.000 claims 34
- 238000000034 method Methods 0.000 claims 34
- 125000003342 alkenyl group Chemical group 0.000 claims 32
- 229910052736 halogen Inorganic materials 0.000 claims 31
- 150000002367 halogens Chemical class 0.000 claims 31
- 239000013078 crystal Substances 0.000 claims 28
- 239000000651 prodrug Substances 0.000 claims 28
- 229940002612 prodrug Drugs 0.000 claims 28
- 150000003839 salts Chemical class 0.000 claims 28
- 239000012453 solvate Substances 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000002252 acyl group Chemical group 0.000 claims 19
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 14
- 150000004677 hydrates Chemical class 0.000 claims 14
- 125000004429 atom Chemical group 0.000 claims 11
- 125000004430 oxygen atom Chemical group O* 0.000 claims 11
- 229910052717 sulfur Inorganic materials 0.000 claims 11
- 125000004434 sulfur atom Chemical group 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 208000012641 Pigmentation disease Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 claims 1
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 claims 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 0 *C1C(C2CCCCC2)=CC2C=C=C/C(/C#N)=C\CC2CC1 Chemical compound *C1C(C2CCCCC2)=CC2C=C=C/C(/C#N)=C\CC2CC1 0.000 description 3
- SAWXBOBEGFDMNS-MSVVQRAFSA-N CC(CC(C=C)/C=C(\C)/N(CC1)CCN1NC)C(C)=N Chemical compound CC(CC(C=C)/C=C(\C)/N(CC1)CCN1NC)C(C)=N SAWXBOBEGFDMNS-MSVVQRAFSA-N 0.000 description 1
- BTIMFUJIIYYWIM-UHFFFAOYSA-N CC1=C(C)N=CCC1CC=C Chemical compound CC1=C(C)N=CCC1CC=C BTIMFUJIIYYWIM-UHFFFAOYSA-N 0.000 description 1
- MTAUERSRIFOGMG-JLHYYAGUSA-N CCCCN(C)/C(/CC)=C/C=C(C)C Chemical compound CCCCN(C)/C(/CC)=C/C=C(C)C MTAUERSRIFOGMG-JLHYYAGUSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023043357A JP2023088968A (ja) | 2017-02-28 | 2023-03-17 | Ｓｉｋインヒビターとしてのピリミドピリミジノンの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762464675P | 2017-02-28 | 2017-02-28 | |
| US62/464,675 | 2017-02-28 | ||
| US201762472468P | 2017-03-16 | 2017-03-16 | |
| US62/472,468 | 2017-03-16 | ||
| PCT/US2018/020335 WO2018160774A1 (en) | 2017-02-28 | 2018-02-28 | Uses of pyrimidopyrimidinones as sik inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023043357A Division JP2023088968A (ja) | 2017-02-28 | 2023-03-17 | Ｓｉｋインヒビターとしてのピリミドピリミジノンの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020509022A JP2020509022A (ja) | 2020-03-26 |
| JP2020509022A5 true JP2020509022A5 (enExample) | 2021-04-15 |
| JP7296318B2 JP7296318B2 (ja) | 2023-06-22 |
Family
ID=63370223
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547113A Active JP7296318B2 (ja) | 2017-02-28 | 2018-02-28 | Ｓｉｋインヒビターとしてのピリミドピリミジノンの使用 |
| JP2023043357A Pending JP2023088968A (ja) | 2017-02-28 | 2023-03-17 | Ｓｉｋインヒビターとしてのピリミドピリミジノンの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023043357A Pending JP2023088968A (ja) | 2017-02-28 | 2023-03-17 | Ｓｉｋインヒビターとしてのピリミドピリミジノンの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11285158B2 (enExample) |
| EP (1) | EP3589284A4 (enExample) |
| JP (2) | JP7296318B2 (enExample) |
| KR (1) | KR20190120331A (enExample) |
| CN (1) | CN111163771B (enExample) |
| AU (1) | AU2018226771B2 (enExample) |
| BR (1) | BR112019017741A2 (enExample) |
| CA (1) | CA3054809A1 (enExample) |
| RU (1) | RU2019129727A (enExample) |
| WO (1) | WO2018160774A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015292818B2 (en) | 2014-07-21 | 2020-01-16 | Dana-Farber Cancer Institute, Inc. | Imidazolyl kinase inhibitors and uses thereof |
| WO2018009544A1 (en) * | 2016-07-05 | 2018-01-11 | The Broad Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
| US11241435B2 (en) | 2016-09-16 | 2022-02-08 | The General Hospital Corporation | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis |
| CN111163771B (zh) * | 2017-02-28 | 2023-07-14 | 通用医疗公司 | 嘧啶并嘧啶酮类作为sik抑制剂的用途 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US20230048132A1 (en) * | 2018-12-28 | 2023-02-16 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| CN118930524A (zh) | 2019-05-10 | 2024-11-12 | 德西费拉制药有限责任公司 | 苯基氨基嘧啶酰胺自噬抑制剂及其使用方法 |
| SG11202112171XA (en) | 2019-05-10 | 2021-12-30 | Deciphera Pharmaceuticals Llc | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| AU2020297422B2 (en) | 2019-06-17 | 2024-03-21 | Deciphera Pharmaceuticals, Llc | Aminopyrimidine amide autophagy inhibitors and methods of use thereof |
| AU2020328025A1 (en) | 2019-08-14 | 2022-03-03 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| JOP20220087A1 (ar) | 2019-10-11 | 2023-01-30 | Incyte Corp | أمينات ثنائية الحلقة كمثبطات لـ cdk2 |
| GB201915828D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
| EP3901151A1 (en) | 2020-04-21 | 2021-10-27 | iOmx Therapeutics AG | Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof |
| US20230192701A1 (en) | 2020-04-28 | 2023-06-22 | Iomx Therapeutics Ag | Bicyclic kinase inhibitors and uses thereof |
| AU2021343539A1 (en) * | 2020-09-21 | 2023-05-18 | Soltego, Inc. | Sik inhibitors and methods of use thereof |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| IL312288A (en) | 2021-10-19 | 2024-06-01 | Iomx Therapeutics Ag | A process for preparing an inhibitor of SIK3 and intermediates obtained in the process |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CN114414681B (zh) * | 2021-12-30 | 2024-10-11 | 珠海天祥粤澳质量技术服务有限公司 | 一种同时测定化妆品中的多种色素的方法 |
| EP4257132A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Sik3 inhibitors for treating diseases resistant to death receptor signalling |
| CA3253413A1 (en) * | 2022-05-17 | 2023-11-23 | Soltego, Inc. | PYRIMIDOPYRIMIDONE COMPOUNDS AND THEIR METHODS OF USE |
| WO2025059216A1 (en) * | 2023-09-12 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Treatment of high-grade serous carcinoma |
| WO2025157389A1 (en) | 2024-01-22 | 2025-07-31 | Iomx Therapeutics Ag | Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors |
| CN118546871B (zh) * | 2024-05-10 | 2025-05-06 | 未来智人再生医学研究院(广州)有限公司 | 一种人多能干细胞分化为间充质干细胞的方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4231559B2 (ja) | 1997-04-23 | 2009-03-04 | オリザ油化株式会社 | リポキシゲナーゼ阻害剤 |
| ES2310039T3 (es) | 1998-05-26 | 2008-12-16 | Warner-Lambert Company Llc | Pirimidinas biciclicas y 3,4-dihidropirimidinas biciclicas como inhibidores de la proliferacion celular. |
| EP1123295B1 (en) | 1998-10-23 | 2004-09-29 | F. Hoffmann-La Roche Ag | Bicyclic nitrogen heterocycles |
| WO2001029042A1 (en) | 1999-10-21 | 2001-04-26 | F. Hoffmann-La Roche Ag | Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase |
| US20050202001A1 (en) | 2002-04-24 | 2005-09-15 | Han-Mo Koo | Enhancement of human epidermal melanogenesis |
| US7084270B2 (en) | 2002-08-14 | 2006-08-01 | Hoffman-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| EP1544295A4 (en) | 2002-08-21 | 2005-12-28 | Proteinexpress Co Ltd | SALT-INDUCIBLE KINASES 2 AND THEIR USE |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| US7112676B2 (en) | 2002-11-04 | 2006-09-26 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| MXPA05005547A (es) | 2002-11-28 | 2005-07-26 | Schering Ag | Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos. |
| BRPI0409366A (pt) | 2003-04-10 | 2006-04-25 | Hoffmann La Roche | compostos de pirimido |
| US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| BRPI0413005A (pt) | 2003-07-29 | 2006-09-26 | Irm Llc | compostos e composições como inibidores da proteìna cinase |
| TW200610762A (en) | 2004-06-10 | 2006-04-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| KR100853975B1 (ko) | 2004-08-31 | 2008-08-25 | 에프. 호프만-라 로슈 아게 | 3-페닐 디히드로피리미도[4,5-ｄ]피리미디논의 아미드유도체, 이의 제조 방법 및 약제로서의 용도 |
| WO2006024545A1 (en) | 2004-09-03 | 2006-03-09 | Stichting Voor De Technische Wetenschappen | Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes |
| WO2006074057A2 (en) | 2004-12-30 | 2006-07-13 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| WO2006104917A2 (en) | 2005-03-25 | 2006-10-05 | Glaxo Group Limited | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives |
| GEP20105074B (en) | 2005-12-21 | 2010-09-10 | Novartis Ag | Pyrimidinyl aryl urea derivatives being fgf inhibitors |
| RU2008149245A (ru) * | 2006-05-15 | 2010-06-20 | Айрм Ллк (Bm) | Композиции и способы ингибирования рецепторных киназ fgf |
| WO2008060248A1 (en) | 2006-11-15 | 2008-05-22 | S*Bio Pte Ltd. | Indole sustituted pyrimidines and use thereof in the treatment of cancer |
| WO2009073153A2 (en) | 2007-11-28 | 2009-06-11 | Dana Farber Cancer Institute | Small molecule myristate inhibitors of bcr-abl and methods of use |
| US20100056524A1 (en) | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
| WO2009152027A1 (en) | 2008-06-12 | 2009-12-17 | Merck & Co., Inc. | 5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition |
| WO2010017047A1 (en) | 2008-08-05 | 2010-02-11 | Merck & Co., Inc. | Therapeutic compounds |
| EP2488526B1 (en) | 2009-10-14 | 2013-07-24 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis c |
| CN102816162B (zh) | 2011-06-10 | 2016-04-27 | 中国科学院广州生物医药与健康研究院 | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 |
| KR20140078710A (ko) | 2011-09-30 | 2014-06-25 | 온코디자인 에스.에이. | 거대고리 flt3 키나제 억제제 |
| US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
| GB201204384D0 (en) | 2012-03-13 | 2012-04-25 | Univ Dundee | Anti-flammatory agents |
| HUE054031T2 (hu) | 2012-04-24 | 2021-08-30 | Vertex Pharma | DNS-PK inhibitorok |
| US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| JP6576325B2 (ja) | 2013-03-15 | 2019-09-18 | セルジーン シーエーアール エルエルシー | ヘテロアリール化合物およびそれらの使用 |
| SG11201507493SA (en) | 2013-03-15 | 2015-10-29 | Oncodesign Sa | Macrocyclic salt-inducible kinase inhibitors |
| US9783504B2 (en) * | 2013-07-09 | 2017-10-10 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
| AU2015292818B2 (en) | 2014-07-21 | 2020-01-16 | Dana-Farber Cancer Institute, Inc. | Imidazolyl kinase inhibitors and uses thereof |
| DK3172213T3 (da) | 2014-07-21 | 2021-12-13 | Dana Farber Cancer Inst Inc | Makrocykliske kinasehæmmere og anvendelser deraf |
| EP3177295A4 (en) | 2014-08-08 | 2018-06-13 | Dana Farber Cancer Institute, Inc. | Uses of salt-inducible kinase (sik) inhibitors |
| KR101850282B1 (ko) | 2014-11-26 | 2018-05-31 | 한국과학기술연구원 | 단백질 키나아제 저해제로 유용한 헤테로아릴아민 유도체 |
| CN104482860B (zh) | 2014-12-05 | 2017-10-31 | 浙江大学宁波理工学院 | 鱼类形态参数自动测量装置和方法 |
| WO2018009544A1 (en) | 2016-07-05 | 2018-01-11 | The Broad Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
| US11241435B2 (en) | 2016-09-16 | 2022-02-08 | The General Hospital Corporation | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis |
| CN111163771B (zh) * | 2017-02-28 | 2023-07-14 | 通用医疗公司 | 嘧啶并嘧啶酮类作为sik抑制剂的用途 |
-
2018
- 2018-02-28 CN CN201880027619.8A patent/CN111163771B/zh active Active
- 2018-02-28 EP EP18760857.5A patent/EP3589284A4/en active Pending
- 2018-02-28 RU RU2019129727A patent/RU2019129727A/ru unknown
- 2018-02-28 US US16/489,462 patent/US11285158B2/en active Active
- 2018-02-28 AU AU2018226771A patent/AU2018226771B2/en active Active
- 2018-02-28 WO PCT/US2018/020335 patent/WO2018160774A1/en not_active Ceased
- 2018-02-28 BR BR112019017741A patent/BR112019017741A2/pt not_active Application Discontinuation
- 2018-02-28 CA CA3054809A patent/CA3054809A1/en active Pending
- 2018-02-28 KR KR1020197028441A patent/KR20190120331A/ko not_active Ceased
- 2018-02-28 JP JP2019547113A patent/JP7296318B2/ja active Active
-
2021
- 2021-11-22 US US17/532,215 patent/US11878019B2/en active Active
-
2023
- 2023-03-17 JP JP2023043357A patent/JP2023088968A/ja active Pending
- 2023-11-29 US US18/522,929 patent/US20240245695A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020509022A5 (enExample) | ||
| KR100737090B1 (ko) | 축합 이미다졸륨 유도체 | |
| RU2019129727A (ru) | Применения пиримидопиримидинонов в качестве ингибиторов sik | |
| JP2020505376A5 (enExample) | ||
| JP2019527682A5 (enExample) | ||
| ES2594378T3 (es) | Derivados de la bencilidenoguanidina y uso terapéutico para el tratamiento de enfermedades por mal plegamiento proteico | |
| JP2018522866A5 (enExample) | ||
| JP7159440B2 (ja) | ジカチオン化合物及びその製造方法と使用 | |
| JP2017504595A5 (enExample) | ||
| WO2014072486A1 (en) | New benzene sulfonamide thiazole compounds | |
| JP2014520108A5 (enExample) | ||
| JP2020516616A5 (enExample) | ||
| JP2017522304A5 (enExample) | ||
| US20250361218A1 (en) | Agents and methods for treating dysproliferative diseases | |
| CN114008028A (zh) | 抑制癌细胞生长的嘧啶衍生物及其医药用途 | |
| JP6867998B2 (ja) | ガンを処置するのに使用するための置換疎水性ベンゼンスルホンアミドチアゾール化合物 | |
| JP2025131661A (ja) | ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態 | |
| JP2004269469A (ja) | ピリミジン誘導体又はその塩 | |
| JP2021503451A5 (enExample) | ||
| US11219633B2 (en) | Nucleobase analogue derivatives and their applications | |
| JPH11209284A (ja) | 骨形成促進剤 | |
| JP3634328B2 (ja) | 縮合イミダゾリウム誘導体を含む医薬組成物 | |
| WO2019191502A4 (en) | Compounds for treatment of cardiac arrhythmias and heart failure | |
| CN107567439B (zh) | 2-高哌嗪-1-基-4h-1,3-苯并噻嗪-4-酮衍生物和制备2-(高)哌嗪-1,3-苯并噻嗪-4-酮盐酸盐的方法 | |
| CN107056819B (zh) | 一种预防和治疗心肌缺血的药物及其制备方法 |